To email the article, click here or copy and paste this link: https://magyarnemzet.hu/kulfold/az-unios-ugynokseg-nem-tartja-veszelyesnek-az-astrazenecat-9599060/
Wednesday, March 31, 2021 20:15
The studies still did not identify risk factors for either the very rare cases of age-related or clotting-related disorders reported by AstraZeneca’s coronavirus vaccine, the European Medicines Agency (EMA) said on Wednesday. The Amsterdam-based agency, which acts as the European Union’s pharmacovigilance authority, said in a statement that the link between the British-Swedish pharmaceutical company and the University of Oxford’s Vaxzevria vaccine and the very small number of blood clotting cases remained unproven. However, as possible, analysis of possible side effects of the vaccine will continue.
Highlights: AstraZeneca, a British-Swedish pharmaceutical company and the University of Oxford’s anti-coronavirus
the benefits of the vaccine continue to outweigh the risks of possible side effects.
The Agency’s Competent Risk Assessment Committee (PRAC) will publish up-to-date information on the state of play of AstraZeneca’s vaccine testing after its monthly meeting scheduled for next week, they added.
The disease associated with blood clots, which has also caused a dangerous increase in platelet counts in some cases, has so far occurred at a very low rate among those vaccinated with AstraZeneca. According to previous information from the EMA, a few dozen cases of blood clots have been reported in more than 17 million people vaccinated with AstraZeneca in the countries of the European Union and the United Kingdom. The EU Medicines Agency is investigating possible side effects of blood clots and all vaccines that have been approved for use in the EU so far, including Pfizer / BioNtech, Moderna and Johnson & Johnson vaccines.
The EMA is conducting an extraordinary investigation because several countries announced in early March and since then, as a precautionary measure, the use of AstraZeneca vaccine will be temporarily suspended after several cases of blood clots have been reported in vaccinees. The restriction has since been lifted by some countries and confirmed by others. From today, the use of AstraZeneca vaccines in Germany will also be restricted to people over sixty years of age.